Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer Inc
Femme et Homme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017
MAJ Il y a 4 ans
A PHASE II PROSPECTIVE, RANDOMIZED, MULTI-CENTER, DIABETIC MACULAR EDEMA DOSE RANGING, COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04523655 VERSUS LASER THERAPY (DEGAS)
To evaluate efficacy of three dose levels of PF-04523655 versus laser in improving visual acuity in subjects with diabetic macular edema .
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A 12-WEEK PROOF OF CONCEPT STUDY FOR PF-04991532 IN T2DM SUBJECTS
To evaluate the dose response of PF-04991532 administered twice daily over 12 weeks on HbA1c in adults with T2DM on stable doses of metformin.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER
To characterize the safety and efficacy of pregabalin in subjects with GAD at low and high doses relative to placebo and lorazepam following 3 and 6 months of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA
MAJ Il y a 4 ans
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
To evaluate the long term safety, tolerability and efficacy of CP 690,550 including the incidence of Biopsy Proven Acute Rejection (BPAR) (as interpreted by the central pathologist) and treated clinic...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. 235 East 42nd Street, New York, 10017
MAJ Il y a 4 ans
Study to test efficacy, tolerability, safety and pharmacokinetics of Tofacitinib ointment in subjects with mild, moderate or severe chronic plaque psoriasis
1. To characterize the efficacy of tofacitinib ointment (10 mg/g and 20 mg/g) applied once daily (QD) or twice daily (BID) over 12 weeks in subjects with mild or moderate chronic plaque psoriasis comp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
India Glaucoma Outcomes and Treatment Trial
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A Phase 1b/2, Open-Label, Dose-Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Either Crizotinib or PF-06463922 in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer ESTUDIO ABIERTO DE FASE IB/II, DE BÚSQUEDA DE DOSIS, PARA EVALUAR LA SEGURIDAD, LA EFICACIA, LA FARMACOCINÉTICA Y LA FARMACODINÁMICA DE AVELUMAB (MSB0010718C) EN COMBINACIÓN CON CRIZOTINIB O CON PF-06463922 EN PACIENTES CON CARCINOMA DE PULMÓN NO MICROCÍTICO METASTÁSICO O AVANZADO
Phase 1b Primary Objective: - Group A (ALK-negative): To determine MTD and the recommended Phase 2 dose (RP2D) of the combination of avelumab with crizotinib. - Group B (ALK-positive): To determine th...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis
The primary objective of this endpoint study is to evaluate the safety of tofacitinib at two doses versus TNFi; the co-primary endpoints are adjudicated major adverse cardiovascular events (MACE) and ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY
-Demonstrate superior analgesic efficacy of tanezumab 20 mg SC versus matching placebo SC at Week 8 in subjects, with cancer pain predominantly due to bone metastasis, receiving background opioid ther...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A clinical study evaluating the safety, tolerability, and immune response to HPV vaccine given together with Bivalent RLP2086 vaccine in healthy subjects ≥ 11 to < 18 years of age
To demonstrate the immune response (based on geometric mean titer [GMT]) induced by Gardasil given with bivalent rLP2086 vaccine (Group1) is noninferior to the immune response induced by Gardasil alon...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
12
13
14
15
16
17
18
19
20
21
Suivant